Trials / Not Yet Recruiting
Not Yet RecruitingNCT07357220
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of AK112 in Combination With VG2025 in Patients With Advanced Colorectal Cancer With Liver Metastases
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
Detailed description
This open-label, multicenter, phase Ib/II clinical study aims to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of AK112 in combination with VG2025, in the treatment of advanced colorectal cancer with liver metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VG2025 | Recommended Phase II Dose, Intratumoral Injection, Q4W |
| DRUG | AK112 | 20mg/kg, ivgtt, Q2W |
Timeline
- Start date
- 2026-03-02
- Primary completion
- 2027-02-28
- Completion
- 2028-02-28
- First posted
- 2026-01-21
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07357220. Inclusion in this directory is not an endorsement.